236 results
Page 4 of 12
8-K
EX-99.1
o5ie9nots1mr9v277ucq
14 Mar 19
BioTime ReportS FOURTH Quarter AND FULL YEAR 2018 Financial Results
4:37pm
8-K
tnu6zqelcx8
14 Feb 19
BIOTIME PROVIDES BUSINESS UPDATE including information ON agex, ONCOCYTE and ASTERIAS
8:05am
8-K
EX-99.1
kcjgobtt
14 Feb 19
BIOTIME PROVIDES BUSINESS UPDATE including information ON agex, ONCOCYTE and ASTERIAS
8:05am
424B3
r9iktx9htjk3xra1s1c
4 Feb 19
Prospectus supplement
5:52pm
S-4/A
xjm3u 0q2
14 Jan 19
Registration of securities issued in business combination transactions (amended)
12:00am
S-4
lszwlgf3zveb2
4 Jan 19
Registration of securities issued in business combination transactions
5:05pm
425
1eu0xfzfu cat7qh
8 Nov 18
Business combination disclosure
9:54pm
425
EX-2.1
9dcaq1b103f7 vh0
8 Nov 18
Business combination disclosure
6:41am
425
lnnj9pvs 3q
8 Nov 18
Business combination disclosure
6:41am
425
EX-99.1
z114jsh4 8i404a3
8 Nov 18
Business combination disclosure
6:41am
8-K
EX-2.1
a070keri9os6gvm5w
8 Nov 18
BioTime and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company
6:41am
8-K
h624 ks892bm1fs0dc
8 Nov 18
BioTime and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company
6:41am
8-K
EX-99.1
1vidxq
8 Nov 18
BioTime and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company
6:41am
8-K
EX-99.1
m5flj7wyih2vkws 6eha
8 Nov 18
BioTime ReportS Third Quarter 2018 Financial Results AND PROVIDES BUSINESS UPDATE
6:40am
425
EX-99.1
5iqqlg6d52wa6 xvm
8 Nov 18
Business combination disclosure
6:40am